Akari Therapeutics

Cash was 7.7 million dollars at June 30, 2026; the company previously disclosed substantial doubt about its ability to continue as a going concern. It recorded Q1 2026 non‑cash impairments to goodwill (8.4 million dollars) and AKTX‑101 IPR&D (3.7 million dollars).

Debt obligations are modest but the business model is structurally cash consumptive. An equity line with White Lion and frequent equity issuances raise dilution risk; authorized shares were increased materially in June 2026. Liquidity is measured in quarters barring additional raises.